---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-022877"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:56:21.450105+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# DiaMedica reports positive Phase 2 preeclampsia data: BP reductions, no placental transfer

## Summary
- DM199 highest dose (Cohort 9, n=3): SBP -35 mmHg (p<0.05), DBP -15 mmHg (p<0.05) at 5 min post-infusion.
- Pooled cohorts 6-9 (n=12) showed sustained BP reductions at 5 min, 30 min, and 24 hours (p≤0.0031).
- No placental transfer; no serious TEAEs; mild nausea (14%), headache (11%), flushing (4%); no discontinuations.
- Uterine artery pulsatility index reduced 13.2% (p=0.0003), indicating improved placental perfusion.
- Study to proceed with dose expansion (Part 1b) and initiate fetal growth restriction cohort (Part 3).

## SEC filing metadata
- accession: 0001437749-25-022877
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774925022877/0001437749-25-022877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774925022877/dmtp20250716_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-022877
- JSON: https://secwatch.observer/filing/0001437749-25-022877.json
- Plain text: https://secwatch.observer/filing/0001437749-25-022877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.